Effects of statins on triglyceride metabolism.
Hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or "statins," have been extremely efficacious in decreasing low-density lipoprotein (LDL) cholesterol levels in patients with hypercholesterolemia and in treating patients with dysbetalipoproteinemia, a relatively rare form of hyperlipidemia. Clinical trials have indicated that statins can significantly lower very-low-density lipoprotein (VLDL) triglyceride levels, although the central mechanism of action of statins-i.e., increasing the number of LDL receptors-would appear to suggest that they would have no significant effect on VLDL levels. Through a review of published data from animal and human studies, this article addresses the important clinical question of how drugs that inhibit the rate-limiting enzyme for cholesterol can affect triglyceride metabolism.